Arca
Skip to content
Tools
Tools

GUCY2C: Guanylyl cyclase C

Guanylyl cyclase that catalyzes synthesis of cyclic GMP (cGMP) from GTP.

  • Drugs that act on it: 4
  • Approved: 2
  • In phases 1 to 3: 2
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on GUCY2C, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody-drug conjugate 1
  • Protein or peptide 3

Approved2

  • Linaclotide
  • Plecanatide

Phase 30

    Phase 22

    • Dolcanatide
    • Indusatumab vedotin

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 3 of 4 act as: Heat-stable enterotoxin receptor agonist; the rest name their own mechanism.
      LinaclotideBoxed warningApprovedAbbVieProtein or peptideAgonist6
      PlecanatideBoxed warningApprovedBausch HealthProtein or peptideAgonist1
      DolcanatidePhase 2Bausch HealthProtein or peptideAgonist0
      Indusatumab vedotinPhase 2Takeda Pharmaceuticals USAAntibody-drug conjugateBinding agentHeat-stable enterotoxin receptor binding agent0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 7 in all, from ClinicalTrials.gov.
      MRI Parameters as Biomarkers in Cystic Fibrosis (FEMPTO)LinaclotideNot applicableNot yet recruitingUniversity of NottinghamAug 21, 2026
      This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FCPlecanatidePhase 2Active, not recruitingBausch Health Americas, Inc.Jul 23, 2026
      Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic FibrosisLinaclotideEarly phase 1RecruitingUniversity of NottinghamMay 6, 2026
      "Efficacy and Safety of Linaclotide in Chronic Constipation"LinaclotidePhase 4Not yet recruitingMd Mehedi ShahriarFeb 25, 2026
      A Study of Virtual Reality and Linaclotide for IBS-CLinaclotideNot applicableRecruitingMayo ClinicApr 3, 2023
      Linaclotide in Treating Patients With Stages 0-3 Colorectal CancerLinaclotidePhase 2Active, not recruitingSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityJan 8, 2019
      Efficacy of Linaclotide in Type II Diabetics With Chronic ConstipationLinaclotidePhase 4Active, not recruitingTexas Tech University Health Sciences Center, El PasoApr 18, 2017

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Congenital diarrhea 60.74
      • Meconium ileus0.72
      • Intestinal obstruction in the newborn due to guanylate cyclase 2C deficiency0.68
      • Diarrheal disease0.62
      • Constipation disorder0.58
      • Chronic constipation0.39
      • Congenital sodium diarrhea0.38
      • Duodenal atresia0.33
      • Familial isolated congenital asplenia0.33
      • Abnormal biliary tract morphology0.33

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1795197, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-20. Gene name, function (UniProt P25092, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.